"Ki-67 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Descriptor ID |
D019394
|
MeSH Number(s) |
D12.776.660.625.500 D23.050.290.500 D23.101.140.400
|
Concept/Terms |
Ki-67 Antigen- Ki-67 Antigen
- Antigen, Ki-67
- Ki 67 Antigen
- Antigen Ki-67
- Antigen Ki 67
- Ki-67, Antigen
- MIB-1 Antigen
- Antigen, MIB-1
- MIB 1 Antigen
- MIB-1 Protein
- MIB 1 Protein
- Antigen Ki67
- Ki67, Antigen
|
Below are MeSH descriptors whose meaning is more general than "Ki-67 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-67 Antigen".
This graph shows the total number of publications written about "Ki-67 Antigen" by people in this website by year, and whether "Ki-67 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 4 | 4 |
1995 | 0 | 11 | 11 |
1996 | 2 | 5 | 7 |
1997 | 0 | 8 | 8 |
1998 | 2 | 14 | 16 |
1999 | 2 | 5 | 7 |
2000 | 1 | 12 | 13 |
2001 | 2 | 8 | 10 |
2002 | 2 | 9 | 11 |
2003 | 3 | 8 | 11 |
2004 | 3 | 9 | 12 |
2005 | 2 | 16 | 18 |
2006 | 1 | 13 | 14 |
2007 | 1 | 11 | 12 |
2008 | 2 | 11 | 13 |
2009 | 4 | 11 | 15 |
2010 | 3 | 13 | 16 |
2011 | 3 | 12 | 15 |
2012 | 2 | 10 | 12 |
2013 | 4 | 15 | 19 |
2014 | 3 | 9 | 12 |
2015 | 3 | 7 | 10 |
2016 | 4 | 6 | 10 |
2017 | 3 | 2 | 5 |
2018 | 1 | 6 | 7 |
2019 | 3 | 4 | 7 |
2020 | 1 | 7 | 8 |
2021 | 0 | 3 | 3 |
2022 | 0 | 8 | 8 |
2023 | 0 | 8 | 8 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-67 Antigen" by people in Profiles.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs). Pathol Res Pract. 2024 Mar; 255:155163.
-
The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study. Surgery. 2024 01; 175(1):80-89.
-
Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83.
-
DNA Methylation Identifies Epigenetic Subtypes of Triple-Negative Breast Cancers With Distinct Clinicopathologic and Molecular Features. Mod Pathol. 2023 11; 36(11):100306.
-
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer. 2023 09; 191:113250.
-
Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Am J Surg Pathol. 2023 08 01; 47(8):849-858.
-
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):664-672.
-
Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated? Clin Breast Cancer. 2023 06; 23(4):415-422.
-
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. Ann Surg Oncol. 2023 Apr; 30(4):2111-2118.